+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Microscopic Polyangiitis Drug"

No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.

Microscopic Polyangiitis (MPA) is a rare autoimmune disorder that affects the small blood vessels in the body. It is a type of vasculitis, which is an inflammation of the blood vessels. Treatment for MPA typically involves the use of cardiovascular drugs, such as corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific parts of the immune system and reduce inflammation. The MPA drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of MPA, as well as the development of new treatments and therapies. Companies in the MPA drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more